Publisher
Springer Science and Business Media LLC
Subject
Otorhinolaryngology,Surgery
Reference45 articles.
1. Guidi A, Codecà C, Ferrari D (2018) Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol 35(3):1–2
2. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127
3. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S (2019) Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the Head and Neck: efficacy and safety in CheckMate 141 by prior Cetuximab UseNivolumab in R/M SCCHN: outcomes by prior Cetuximab exposure. Clin Cancer Res 25(17):5221–5230
4. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965
5. D’Cruz AK, Chaukar D, Gupta T (2012) Evidence based management of guidelines in India: Guidelines for Head and Neck Cancer, Vol X1 (Part A).“. General Principles and Outline of Management”. Tata Memorial Centre, Mumbai. :1–8